| Analysis | Metabolite Name | Measured Value | Units | Group | TIMEPOINT |
|---|---|---|---|---|---|
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.2550 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.3749 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.3762 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.3770 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.4303 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.4353 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.4419 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.4481 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.4726 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.4776 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.4910 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.5009 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.5144 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.5260 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.5388 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.5467 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.5536 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.5633 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.5637 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.5759 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.5770 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.5946 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.6146 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.6174 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.6259 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.6349 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.6358 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.6502 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.6639 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.6641 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.6654 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.6681 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.6733 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.6906 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.6973 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.7044 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.7054 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.7142 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.7255 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.7361 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.7463 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.7467 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.7522 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.7599 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.7674 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.7736 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.7861 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.7891 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.7907 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.7934 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.7974 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.7985 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.8285 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.8327 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.8417 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.8420 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.8431 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.8503 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.8534 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.8548 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.8576 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.8633 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.8678 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.8696 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.8707 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.8747 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.8797 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.8831 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.8846 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.8885 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.8895 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.8935 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.8969 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.8974 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.9036 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.9158 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.9173 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.9184 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.9191 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.9250 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.9252 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.9283 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.9337 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.9420 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.9449 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.9553 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.9617 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.9693 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.9723 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.9733 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.9786 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.9850 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 0.9921 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.0000 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.0036 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.0079 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.0103 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.0113 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.0210 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.0239 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.0312 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.0371 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.0561 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.0674 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.0888 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.0911 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.0961 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.1028 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.1125 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.1285 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.1441 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.1463 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.1476 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.1527 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.1557 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.1569 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.1601 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.1603 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.1761 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.1788 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.1816 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.1878 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.1992 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.2054 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.2093 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.2129 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.2292 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.2320 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.2345 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.2444 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.2449 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.2517 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.2541 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.2660 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.2780 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.2933 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.3281 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.3301 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.3306 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.3440 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.3707 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.3993 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.4052 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.4055 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.4122 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.4129 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.4171 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.4575 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.4898 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.4925 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.4954 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.5007 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.5096 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.5627 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.5645 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.5678 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.5983 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.6028 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.6228 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.6426 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.6715 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.7376 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.7454 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.7889 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.8144 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.8223 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.8831 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.8847 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.9152 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.9508 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 1.9905 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 2.0746 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 2.1179 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 2.1624 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 2.2065 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 2.2366 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 2.2538 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 2.2633 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 2.3435 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 2.4160 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 2.4300 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 2.5897 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 2.6281 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 2.6391 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 2.8413 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 3.6916 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | arachidonate (20:4n6) | 4.3866 | scaled units | High-Dose | +4HR POST INFUSION |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|